Excessive Pricing Across the Atlantic
1 PM EDT
In Europe, dominant companies can be found to have abused their dominant position by charging excessive and unfair prices. Competition agencies in Italy, the UK as well as the European Commission have all either concluded or launched unfair pricing cases recently. Most notably, for example, in the UK the CMA issued fines totaling £90million in Pfizer/Flynn for excessive and unfair pricing of an epilepsy drug. Our speakers will consider the law and economics underlying excessive and unfair pricing cases and in particular:
* Law and economics in unfair pricing cases
* Basis for, and lessons learned from, recent cases, particularly Pfizer/Flynn
* Economic policy and competition interventions
FREE: Antitrust Section Members, Government, Non-profit Employees, Students. $25.00 Other Non-Members.
Explore Section benefits or call 1-800-285-2221 to join. Code RAT14IP25. For this and all upcoming events visit http://ambar.org/atevents.
CLE: The ABA is not seeking CLE credit for this program.
Audio Archive: Provided all releases are obtained, MP3 recordings of this program will be available to Section members on the Committee Program Audio page.